Prevents post-menopausal osteoporosis. ANDA 78998, held by Orbion Pharmaceuticals. Ibandronate Sodium.
As of Nov 21, 2026, ANDA 78998 (Ibandronate Sodium), held by Orbion Pharmaceuticals, was first approved by FDA on Mar 19, 2012, with 4 approved supplements and 0 published complete response letters.
Ibandronate Sodium Tablets are a bisphosphonate indicated for the treatment and prevention of post-menopausal osteoporosis. Limitations of Use The optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use.. 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate Sodium Tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium increases bone mineral density (BMD) and reduces the incidence of vertebral fractures. 1.2 Important Limitations of Use The optimal duration of use has not been determined.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 19, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 150MG BASE · tablet;oral | Ibandronate Sodium | Rx |
| Feb 3, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 15, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 15, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 15, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 19, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters